DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- ...

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for HER2 testing if the cancer is invasive, metastatic, and/or recurrent.

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

Oncopathology or cancer pathology is a specialised branch of pathology focused on diagnosing and characterising tumours ...

Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...